Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Colorado BioScience

03:20 EST 22nd January 2018 | BioPortfolio

Here are the most relevant search results for "Colorado BioScience" found in our extensive news archives from over 250 global news sources.

More Information about Colorado BioScience on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Colorado BioScience for you to read. Along with our medical data and news we also list Colorado BioScience Clinical Trials, which are updated daily. BioPortfolio also has a large database of Colorado BioScience Companies for you to search.

Showing News Articles 1–25 of 75 from Colorado BioScience

Friday 19th January 2018

Friday Policy Update 1/19/2018

Another week goes by and we continue to strongly advocate for the repeal of the medical device excise tax. This week in DC, the House passed the continuing resolution (CR) to fund the government until February 16th. Included in the CR is a 2-year retroactive suspension of the device tax and a 6-year reauthorization of Children’s Health Insurance Program (CHIP), the longest reauthoriz...

Tuesday 16th January 2018

Millennials: Training Talent

State-Funded Program Connects Interns to Bioscience Careers Colorado’s commitment to growing a strong bioscience workforce begins with training up-and-coming talent. A state-funded program focused on advancing the careers of next-generation innovators provides companies in the state’s designated Innovation Industries dollars to hire and train Millennial interns. The program connects com...

Friday 12th January 2018

Friday Policy Updates 1/12/2018

UNDER THE GOLD DOME – THE 71ST GENERAL ASSEMBLY The 2018 Colorado Legislative session started this week and kicked off with several industry related health care bills. The CBSA team is already hard at work advocating on behalf of the industry and our members. So far, legislation has been introduced on Opioid Misuse Prevention, Diabetes Drug Pricing Transparency Act, Clinical Practice for Opioi...

Wednesday 10th January 2018

RxRevu Unveils New SwiftRx® Platform at 36th Annual J.P.Morgan Healthcare Conference

RxRevu, the industry leader in Prescription Decision Support, will unveil its new SwiftRx® platform while attending the 36th Annual J.P.Morgan Healthcare Conference on January 8th in San Francisco, CA. Building on RxRevu’s proven success, this unique and revolutionary platform helps doctors choose which drug to prescribe through a proprietary guidance-based approach that considers the p...

Tuesday 9th January 2018

miRagen: Comprehensive, microRNA Targeted Therapies

Tiny Molecules Modulate Cellular Processes and Can Re-Program Cells Involved in Disease Bill Marshall was in Vienna, Austria, when he got the news. A prominent researcher had, for the first time, found a way to use a molecular cousin of DNA, called a microRNA, to prevent heart failure in mice with high blood pressure. In the world of cardiac medicine, “that was a eureka moment,” said Marshal...

Monday 8th January 2018

Inocucor Raises $9.5 Million in Series B Second Close Led by Pontifax AgTech, Raising Total Proceeds of Series B Financing to $38.5 Million

Inocucor Raises $9.5 Million USD ($12.1 Million CAD) in Series B Second Close Led by Pontifax AgTech, Raising Total Proceeds of Series B Financing to $38.5 Million USD ($50.9 Million CAD) Ben Belldegrun, Managing Partner and Co-Founder of Pontifax AgTec Inocucor Corporation, a developer and producer of biological crop inputs for high-value produce and row crops, announced the $9.5 milli...

ARTICULUS BIO TO PRESENT AT 10TH ANNUAL BIOTECH SHOWCASE CONFERENCE DURING JP MORGAN HEALTHCARE WEEK

Articulus Bio, LLC, a development-stage orthopedic medical device platform focused on total joint replacement, today announced that Adam B. Rubenstein, Chief Executive Officer, will present at the 10th annual Biotech Showcase Conference on Wednesday, January 10, 2018, at 3:15 p.m. PST. The conference is being held at the Hilton Union Square Hotel in San Francisco, California. The presenta...

Friday 5th January 2018

Friday Policy Updates – 1/5/2018

Under the Gold Dome – The 71st General Assembly The 2018 Colorado Legislative session begins next Wednesday, January 10th! The CBSA team will be busy advocating on behalf of the Colorado Bioscience industry and our members.Be sure to check the weekly policy blog to get ongoing updates regarding happenings during the legislative session. We continue focus on sharing firsthand the...

Wednesday 3rd January 2018

Millennials in Colorado

Expanding our Workforce, Inspiring Our Companies Colorado boasts the fastest-growing Millennial population in the United States. This large demographic group is generally recognized as Americans born between 1980 and 1999. They are young adults just hitting their career stride. In Metro Denver, more than 43 percent of residents hold a bachelor’s degree or better. While Colorado attracts ...

Tuesday 19th December 2017

At the Center of Everything

Our Location Gives BioScience Companies an Advantage Many factors contribute to Colorado’s reputation as an exceptional place to start, grow, commercialize or relocate a life science business. Our collaborative business culture. World-class academic and research institutions. Favorable tax climate. Educated, motivated workforce. Supportive bioscience sector. Our location. For business ...

Friday 15th December 2017

Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)

Primary endpoint of OMERACT-OARSI responder rate at 12 weeks achieved statistical significance (p < 0.001) Ampion™ is the first therapy indicated for signs and symptoms for severe osteoarthritis of the knee and will address a significant treatment gap Conference call, December 14, at 6:30 a.m. MT (8:30 ET) ENGLEWOOD, C...

Thursday 14th December 2017

Denver Business Journal Recognizes Colorado BioScience's Remarkable Year!

The Denver Business Journal wants their readers to know the bioscience industry in our state has enjoyed a record breaking year. Read the full article.  

Tuesday 12th December 2017

2017 Breaks Bioscience Records

$1.2 Billion Year Doubles Amount Raised in 2016 Colorado’s life science companies raised a record $1.2 billion in 2017, doubling the funds raised in the previous year. The funding came through venture capital, debt refinancing, mergers and acquisitions, public offerings and grants. Three major financings contributed to the banner year for fundraising, with Clovis Oncology raising $526...

Friday 8th December 2017

New Partnership Creates the Broadest Suite of Capabilities and Innovative Solutions Available for the Study and Diagnosis of Complex Genetic Variations in Cancer.

KromaTiD Inc. announced today that it has entered into a strategic partnership with Empire Genomics of Buffalo, NY, to provide a single, comprehensive set of genomic products and services. Targeted at oncology researchers and testing labs worldwide, this combined portfolio will help clinicians, researchers and biopharmaceutical companies better understand the complex genetics of patients w...

Tuesday 5th December 2017

Sharklet Moves Out of the Startup Scene

Company Readies for Global Commercialization Sharklet has turned a corner. For the last 10 years, the startup company has worked to develop the chemical-free, micropatterned coating it pioneered to not only prevent contamination by harmful bacteria on medical devices and surfaces, but also promote favorable healing mechanisms. In May of 2017, Peaceful Union, a firm based in Hangzhou, Chi...

Friday 1st December 2017

Cetya Therapeutics Announces Advanced Industries Award

$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program Cetya Therapeutics, Inc. announces the award of a $170,000 Advanced Industries grant from the State of Colorado to support the development of its proprietary receptor ligand-targeted histone deacetylase (HDAC) inhibitors. Targeting has been an effective method for dealing with drug-related toxicities, and ...

Tuesday 28th November 2017

Regenerative Medicine in Colorado

How Researchers and Entrepreneurs are Advancing Human and Animal Health From treating painful skin conditions in children with IPS cells to using stem cells to improve quality of life for injured people and their pets, Colorado boasts intense activity in the field of regenerative medicine. Academic and research institutions, bioscience companies and non-profits in the state all seek new ways to ...

Monday 27th November 2017

Layne Los, PhD, CEO of ClaroLabs announced the company has raised $800K in the first round of a $2M Series A preferred stock offering

Layne Los, PhD, CEO of ClaroLabs announced the company has raised $800K in the first round of a $2M Series A preferred stock offering. The company recently setup operations in a 5000+ sq. ft. facility in Lafayette, CO. Claro Scientific Laboratories, Inc is a clinical reference Lab (CLIA) providing urine drug testing services for Addiction Recovery Clinics, Pain Clinics and a D...

Wednesday 15th November 2017

Ready for Retirees

How the Sector is Preparing for the State’s Shifting Demographics Colorado consistently ranks as a top destination for retirees. With Baby Boomers reaching retirement age at the rate of 10,000 per day, the population of Coloradoans older than 65 will increase from close to 500,000 in 2010 to more than 1.2 million by 2030. What will be the economic, social and health consequences of the o...

Monday 13th November 2017

Former Array Biopharma COO, Dr. David L. Snitman joins AmideBio Business Advisory Board

AmideBio LLC, a privately-held biopharmaceutical company, announced today that Dr. David L. Snitman has joined its business advisory board. Dr. Snitman has extensive experience with company financing as well as building strategic alliances with the pharmaceutical industry. He will be a huge asset to the company as it develops its pipeline of novel drugs targeting diabetes and ...

Thursday 9th November 2017

ImmunoMolecular Therapeutics Launches to Advance Innovative Immuno therapi es for Genetically Defined Type 1 Diabetes and Other Autoimmune Diseases

ImmunoMolecular Therapeutics (IM Therapeutics), a company developing personalized small molecule therapies for the treatment of genetically defined autoimmune diseases, today made its debut as a spinout from the Barbara Davis Center for Diabetes at the University of Colorado. IM Therapeutics was co-founded by Peter Gottlieb, M.D., Professor of Pediatrics and Medicine with tenu...

Tuesday 7th November 2017

TranS1: Innovative Products and Partnerships

Supporting Spine Surgery’s Invention Engine Minimally invasive spine surgery sounds like an oxymoron. But that’s precisely the goal at TranS1, headquartered in a restored Victorian home in Denver’s hip Highlands neighborhood. The company, led by CEO Jeff Schell, is focused on optimizing spine surgery while reducing patient trauma. TranS1 is accomplishing that goal with a growing li...

Tuesday 31st October 2017

Champions for Bioscience

Accelerating Industry Success through Advocacy The CBSA team leads advocacy efforts on behalf of the industry and our members. We work every day to create an innovation-friendly business environment. Our policy activities at the state and federal level focus on proactive and reactive legislation. Our commitment to strong connections with federal, state and local officials fosters a cultu...

Thursday 26th October 2017

Four Companies Win Their Share of $150,000 in Healthcare Shark-Tank Event

During the 2017 Prime Health Challenge, six healthcare technology startups pitched to representatives from 16 host institutions, including Kaiser Permanente, Metro Community Provider Network, AllHealth Network, Centura, UCHealth, and SCL Health. Over 500 audience members watched as each company competed for an opportunity to prove their solutions with Colorado healthcare institutions. ...

Tuesday 24th October 2017

‘It’s All About the Kids’

Children Inspire the Team at Silvergate Pharmaceuticals As a pharmacist managing some of the largest consumer pharmacies in the country, Frank Segrave saw a need. The majority of medications on his shelves—most of them in tablet or capsule form—were proportioned for adult dosages. To fill a prescription for a child, Segrave had to do what all pharmacists did: crush up the adult pill...


Quick Search
Advertisement

 

News Quicklinks